AI Assistant
Blog
Pricing
Log In
Sign Up
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
